Thomas Hutson, DO, PharmD suggests the areas new research for non-clear cell renal cell carcinoma should explore.
Thomas Hutson, DO, PharmD, director of the Urologic Oncology Program and co-chair of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center and professor of medicine, Texas A&M College of Medicine, suggests the areas new research for non-clear cell renal cell carcinoma (RCC) should explore.
According to Hutson, the next step in research for non-clear cell RCC should focus on further understanding the pathogenesis for each histologic subtype. While newer generation drugs such as lenvatinib (Lenvima) and everolimus (Zortress) show higher activity than earlier generation drugs, new targeted therapies are needed if the efficacy in non-clear cell RCC is ongoing to rival the efficacy seen in clear cell RCC.
Hutson says that these newer-generation drugs will most likely not be studied in large phase 3 trials as these histologies are rare. It would take years to accrue enough patients for regulatory approval, explains Hutson. The best thing to do, he says, is too keep researching and make the data publicly available to health care providers in order to help them make informed treatment decisions.
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
May 6th 2024The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target action date has been set for February 28, 2025.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Tolerability Helps Decide Third-Line Treatment in Advanced RCC
April 30th 2024During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Read More
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More